Valneva SE (0OB3.L)
EUR 1.82
(2.0%)
EUR 1.82
(2.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 132.76 Million EUR | 15.06% |
| 2022 | 115.39 Million EUR | 10.51% |
| 2021 | 104.41 Million EUR | 9.03% |
| 2020 | 95.76 Million EUR | 18.36% |
| 2019 | 80.9 Million EUR | 101.92% |
| 2018 | 40.07 Million EUR | -25.93% |
| 2017 | 54.09 Million EUR | -12.1% |
| 2016 | 61.54 Million EUR | -19.62% |
| 2015 | 76.56 Million EUR | 15.95% |
| 2014 | 66.03 Million EUR | 1.75% |
| 2013 | 64.9 Million EUR | 1179.36% |
| 2012 | 5.07 Million EUR | -3.7% |
| 2011 | 5.26 Million EUR | -4.93% |
| 2010 | 5.54 Million EUR | 3.36% |
| 2009 | 5.36 Million EUR | 38.74% |
| 2008 | 3.86 Million EUR | 23.69% |
| 2007 | 3.12 Million EUR | 8.17% |
| 2006 | 2.88 Million EUR | 6.61% |
| 2005 | 2.7 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 159.03 Million EUR | 19.78% |
| 2024 Q2 | 160.54 Million EUR | 0.95% |
| 2023 Q2 | 102.09 Million EUR | -9.47% |
| 2023 Q3 | 134.89 Million EUR | 32.13% |
| 2023 FY | 132.76 Million EUR | 15.06% |
| 2023 Q1 | 112.78 Million EUR | -2.26% |
| 2023 Q4 | 132.76 Million EUR | -1.58% |
| 2022 Q3 | 146 Million EUR | 22.71% |
| 2022 FY | 115.39 Million EUR | 10.51% |
| 2022 Q1 | 48 Million EUR | -54.02% |
| 2022 Q2 | 118.98 Million EUR | 147.87% |
| 2022 Q4 | 115.39 Million EUR | -20.97% |
| 2021 Q2 | 101.31 Million EUR | 3.96% |
| 2021 FY | 104.41 Million EUR | 9.03% |
| 2021 Q4 | 104.41 Million EUR | 0.0% |
| 2021 Q1 | 97.46 Million EUR | 1.77% |
| 2020 FY | 95.76 Million EUR | 18.36% |
| 2020 Q1 | 90.84 Million EUR | 12.28% |
| 2020 Q2 | 102.72 Million EUR | 13.08% |
| 2020 Q3 | 101.21 Million EUR | -1.47% |
| 2020 Q4 | 95.76 Million EUR | -5.39% |
| 2019 Q3 | 80.06 Million EUR | 14.35% |
| 2019 FY | 80.9 Million EUR | 101.92% |
| 2019 Q2 | 70.02 Million EUR | -3.13% |
| 2019 Q1 | 72.28 Million EUR | 80.39% |
| 2019 Q4 | 80.9 Million EUR | 1.05% |
| 2018 Q4 | 40.07 Million EUR | -0.61% |
| 2018 Q2 | 39.03 Million EUR | -5.16% |
| 2018 Q1 | 41.15 Million EUR | -23.92% |
| 2018 FY | 40.07 Million EUR | -25.93% |
| 2018 Q3 | 40.31 Million EUR | 3.29% |
| 2017 Q2 | 54.14 Million EUR | -5.88% |
| 2017 Q4 | 54.09 Million EUR | 4.08% |
| 2017 Q3 | 51.97 Million EUR | -4.01% |
| 2017 FY | 54.09 Million EUR | -12.1% |
| 2017 Q1 | 57.52 Million EUR | -6.53% |
| 2016 FY | 61.54 Million EUR | -19.62% |
| 2016 Q2 | 64.81 Million EUR | -7.39% |
| 2016 Q4 | 61.54 Million EUR | -2.1% |
| 2016 Q3 | 62.86 Million EUR | -3.01% |
| 2016 Q1 | 69.98 Million EUR | -8.59% |
| 2015 FY | 76.56 Million EUR | 15.95% |
| 2015 Q1 | 86.05 Million EUR | 30.31% |
| 2015 Q2 | 83.38 Million EUR | -3.1% |
| 2015 Q3 | 80.81 Million EUR | -3.08% |
| 2015 Q4 | 76.56 Million EUR | -5.26% |
| 2014 FY | 66.03 Million EUR | 1.75% |
| 2014 Q1 | 64.06 Million EUR | -1.29% |
| 2014 Q2 | 63.63 Million EUR | -0.68% |
| 2014 Q4 | 66.03 Million EUR | 2.13% |
| 2014 Q3 | 64.65 Million EUR | 1.61% |
| 2013 FY | 64.9 Million EUR | 1179.36% |
| 2013 Q4 | 64.9 Million EUR | 45.08% |
| 2013 Q3 | 44.73 Million EUR | -4.32% |
| 2013 Q2 | 46.75 Million EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2012 Q2 | 4.6 Million EUR | 0.0% |
| 2012 Q4 | 5.07 Million EUR | 0.0% |
| 2012 FY | 5.07 Million EUR | -3.7% |
| 2011 FY | 5.26 Million EUR | -4.93% |
| 2011 Q2 | 6.16 Million EUR | 0.0% |
| 2011 Q4 | 5.26 Million EUR | 0.0% |
| 2010 Q2 | 5.75 Million EUR | 0.0% |
| 2010 FY | 5.54 Million EUR | 3.36% |
| 2010 Q4 | 5.54 Million EUR | 0.0% |
| 2009 FY | 5.36 Million EUR | 38.74% |
| 2009 Q4 | 5.36 Million EUR | 0.0% |
| 2008 FY | 3.86 Million EUR | 23.69% |
| 2007 FY | 3.12 Million EUR | 8.17% |
| 2006 FY | 2.88 Million EUR | 6.61% |
| 2005 FY | 2.7 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Boiron SA | 6.64 Million EUR | -1898.014% |
| Laboratorios Farmaceuticos Rovi, S.A. | 38.57 Million EUR | -244.181% |
| Vetoquinol SA | 9.66 Million EUR | -1273.983% |
| AB Science S.A. | 16.98 Million EUR | -681.54% |
| Nanobiotix S.A. | 41.66 Million EUR | -218.694% |
| PHAXIAM Therapeutics S.A. | 7.03 Million EUR | -1788.592% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |
| BioSenic S.A. | 15.57 Million EUR | -752.552% |
| ABIVAX Société Anonyme | 44.69 Million EUR | -197.04% |
| Formycon AG | 7.81 Million EUR | -1598.887% |